Focus: Bavarian Nordic is a Denmark-headquartered biotech company specializing in vaccines for infectious diseases and oncology, operating at mid-cap scale with 1,001–5,000 employees. The company focuses on viral vaccine platform technologies with an expansive pipeline spanning endemic diseases, emerging pathogens, and therapeutic cancer vaccines.
Profile data last refreshed 1h ago · AI intelligence enriched 1w ago
Stable — net +4 jobs in 30d
29 added, 25 removed. Backfill posture.
Attractive for vaccine and immunology specialists seeking commercial-stage upside and Phase 3 catalysts, but governance tensions and opaque financials warrant due diligence before committing.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Bavarian Nordic
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Bavarian Nordic's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Bavarian Nordic receives smallpox vaccine order worth more than USD 100m - medwatch.com
Bavarian Nordic receives smallpox vaccine order worth more than USD 100m medwatch.com
Bavarian Nordic sees no commercial potential for hantavirus vaccine - medwatch.com
Bavarian Nordic sees no commercial potential for hantavirus vaccine medwatch.com
Bavarian Nordic falls short of Q1 forecast - medwatch.com
Bavarian Nordic falls short of Q1 forecast medwatch.com
Bavarian Nordic raises 2026 forecast on additional US vaccine contract - ETPharma.com
Bavarian Nordic raises 2026 forecast on additional US vaccine contract ETPharma.com
Bavarian Nordic raises 2026 forecast on additional US vaccine contract - Classic Rock 103.5 WIMZ
Bavarian Nordic raises 2026 forecast on additional US vaccine contract Classic Rock 103.5 WIMZ
Bavarian Nordic raises 2026 forecast on additional US vaccine contract - Reuters
Bavarian Nordic raises 2026 forecast on additional US vaccine contract Reuters
Showing 6 of 10 news items
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles